By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CRISPR Therapeutics 

675 West Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-580-9212 Fax: n/a


CRISPR Therapeutics is a leading gene editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working on a number of wholly-owned programs to treat serious diseases with high unmet need.


November 2013


Founders: Rodger Novak, Emmanuelle Charpentier, Shaun Foy

Scientific Founders: Chad Cowan, Daniel Anderson, Stephen Elledge, Craig Mello, Matthew Porteus

CEO and Co-founder: Rodger Novak

CFO: Marc Becker

CSO (Scientific): Sven Ante (Bill) Lundberg


Please click here for CRISPR Therapeutics job opportunities.


Key Statistics

Ownership: Public

Web Site: CRISPR
Symbol: CRSP

Company News
CRISPR (CRSP) And Casebia Therapeutics Announce Exclusive Development And Option Agreement With StrideBio 4/17/2017 8:18:28 AM
Patent Fight Continues as CRISPR (CRSP), Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision 4/13/2017 8:19:07 AM
CRISPR (CRSP) And Casebia Therapeutics Announce Commercial License Agreement With MaxCyte, Inc. 3/14/2017 8:09:05 AM
CRISPR (CRSP) Announces The Appointment Of Jon Terrett, Ph.D. To Head Of Immuno-Oncology Research And Translation 2/28/2017 10:19:02 AM
CRISPR (CRSP), Intellia, Caribou Biosciences And ERS Genomics Provide Update On CRISPR/Cas9 U.S. Patent Interference Proceedings And Grants Of Corresponding Patents In The U.K. 2/16/2017 7:06:22 AM
CRISPR (CRSP)'s Surprisingly Low IPO… Why Are Investors Discouraged? 10/21/2016 6:53:29 AM
CRISPR (CRSP) IPO Brings Home $56 Million, Half of What Its Rival Took in Earlier This Year 10/19/2016 5:43:31 AM
Gene Editing Phenom CRISPR (CRSP) Files for $90 Million IPO 9/12/2016 6:10:31 AM
Bayer (BAY) and CRISPR Form 80 Employee Joint Venture Named Casebia Therapeutics in Boston Area 8/19/2016 5:59:17 AM
CRISPR Gene Editing Reveals New Therapeutic Approach For Sickle Cell Disease 8/15/2016 8:47:46 AM